Category Archives: Pharmacogenomics

The Pharmacogenomics Market report emphasizes Key players strategic movements including public relations activities, brand expansions, and product releases. It furnishes about Pharmacogenomics industry supply chain, processing techniques, market entry strategies, investment plans, retailers, and the economic impact on the stock exchange. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client of the Pharmacogenomics Market. This report also include some market-related illustrations and presentations, including pie charts, which represent the percentage division of strategies adopted by the major players in the global market.

Competitive Landscape

Global Pharmacogenomics market is highly cleft and the key players have used numerous plans such as new product launches, acquisitions, mergers, collaborations, innovation in products, expansions, agreements, joint ventures, and others to increase their footmarks in this market.

For Better Understanding, Download Free Sample Copy Of Pharmacogenomics Market Report In Just One Single Step At:https://marketresearch.biz/report/pharmacogenomics-market/request-sample

Key companies profiled in Pharmacogenomics Market report are: Empire Genomics LLC, Thermo Fisher Scientific Inc, Hoffmann-La Roche AG, Assurex Health Inc, Illumina Inc, Myriad Genetics Inc, OPKO Health Inc (GeneDx), Dynamic DNA Laboratories, OneOme LLC and Abbott Laboratories

The report further provides the following information:

Comprehensive analysis of the factors, drivers, and restraints impacting the share, size, and overall growth of the market.

Careful segregation of the market into different segments and in-depth research into the individual segments.

An exhaustive study of the regional and competitive aspects influencing the development of the market.

The report offered Segmentation:

Segmentation by technology:

Polymerase Chain ReactionMicroarraySequencingMass SpectrometryElectrophoresisOthersSegmentation by application:

OncologyInfectious diseasesCardiovascular diseasesNeurological diseasesPsychiatryPain managementOthersSegmentation by end user:

Hospitals and clinicsResearch institutionsAcademic institutes

All of the Technology, Application, End User, And Region segments of the global Pharmacogenomics market included in the report are deeply analyzed based on CAGR, market size, and other crucial factors. The segmentation study provided by the report authors could help players and investors to make the right decisions when looking to invest in certain market segments.

Regional Analysis:

Objective of Studies:

1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Pharmacogenomics market.

2. To provide insights about factors affecting the market growth. To analyse the Pharmacogenomics market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.

3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.

4. To provide country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analysing their core competencies, and drawing a competitive landscape for the market.

7. To track and analyse competitive developments such as strategic alliances, joint ventures, mergers and acquisitions, new product developments, and research and developments in the global Pharmacogenomics market.

Customize Report AndInquiry For The Pharmacogenomics Market Report:https://marketresearch.biz/report/pharmacogenomics-market/#inquiry

Table of Content

1 Pharmacogenomics Market Overview

2 Global Pharmacogenomics Market Competition by Manufacturers

3 Global Pharmacogenomics Production Market Share by Regions

4 Global Pharmacogenomics Consumption by Regions

5 Global Pharmacogenomics Production, Revenue, Price Trend by Type

6 Global Pharmacogenomics Market Analysis by Applications

7 Company Profiles and Key Figures in Pharmacogenomics Business

8 Pharmacogenomics Manufacturing Cost Analysis

9 Marketing Channel, Distributors and Customers

10 Market Dynamics

11 Global Pharmacogenomics Market Forecast

12 Research Findings and Conclusion

13 Methodology and Data Source

Who we are and what we do:

MarketResearch.biz (https://marketresearch.biz) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined, we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:[emailprotected]

Find More Reports:

Interior Doors Market

View original post here:
Pharmacogenomics Market Report Offers A One-Stop Solution To All The Key Players | Dynamic DNA Laboratories, Empire Genomics LLC and Abbott...

DUBLIN, Jan. 31, 2020 /PRNewswire/ -- The "Global Drug Discovery Market 2019-2027" report has been added to ResearchAndMarkets.com's offering.

There are significant market opportunities for growth in the drug discovery market. Many healthcare industries are making investments in improving Big Data analytics to reduce inefficiency and provide services at affordable costs. The rising demand for specialty medicine is also expected to boost the small molecule drug discovery and hence, create growth opportunities for the drug discovery market.According to this research, the global drug discovery market is estimated to grow exponentially during the forecasting period 2019-2027 in terms of revenue at a CAGR of 8.28%.

An increase in the aged population, rise in healthcare expenses, growth in lifestyle-oriented diseases, and technological advancements are the major factors that are driving the overall growth of the drug discovery market. Rigid government regulations and poor reimbursement policies are some of the challenges that are restraining market growth.

Regional Outlook

The drug discovery market in Asia-Pacific is projecting an upward trend, and it is fastest-growing among the regions. The increasing GDP of various countries in the region have influenced the market growth. In countries like China and India, public as well as private sectors are investing huge amounts to support drug discovery.

Japan is known for its technological advancements in several industries. For instance, Japanese corporations have invented a revolutionary system named Peptide Discovery Platform System (PPDS), which helps to manually create millions of various kinds of peptides and extract it for the new drug. This invention has given a new approach to drug discovery.

Agilient Technologies, Inc. is a public research, development and manufacturing company that provides bio-analytical solutions and services to different sectors like diagnostics and genomics, chemical analysis, life sciences, electronics industries, and communications across the world. The company conducts its research to produce innovative and advanced products & services. The company was awarded as one of America's Best Employer For Diversity 2019 by Forbes.

Key Topics Covered:

1. Global Drug Discovery Market - Summary

2. Industry Outlook2.1. Market Definition2.2. Porter's Five Forces Model2.3. Pestle Outlook2.4. Regulatory Framework2.5. Value Chain Outlook2.6. Market Attractiveness Index2.7. Key Insight2.8. Market Drivers2.8.1. Growing Aged Population2.8.2. Technological Advancements2.8.3. Rise in the Healthcare Expenditure2.8.4. Surge in Lifestyle Oriented Diseases2.9. Market Restraints2.9.1. Delay in Product Launches2.9.2. Restricting Growth Rate of A Drug Due to Generic Drugs2.10. Market Opportunities2.10.1. Significant Investment By Healthcare Industries in Improving Big-Data Analytical Capabilities2.10.2. Rising Demand for Specialty Medicines2.11. Market Challenges2.11.1. Poor Reimbursements Policies in Emerging Nations2.11.2. Stringent Government Regulations

3. Drug Discovery Market Outlook - By Drug Type3.1. Small Molecule Drug3.2. Biologic Drug

4. Drug Discovery Market Outlook - By Technology4.1. High Throughput Screening4.2. Biochips4.3. Bioinformatics4.4. Pharmacogenomics and Pharmacogenetics4.5. Combinatorial Chemistry4.6. Nanotechnology4.7. Spectroscopy4.8. Metabolomics4.9. Other Technologies

5. Drug Discovery Market Outlook - By Service5.1. Drug Metabolism and Pharmacokinetics (DMPK) Services5.2. Chemical Services5.3. Biological Services5.4. Other Pharmaceutical Services

6. Drug Discovery Market Outlook - By End-User6.1. Research Institutes6.2. Pharmaceutical Companies6.3. Contract Research Organizations (CROs)6.4. Other End-Users

7. Drug Discovery Market - Regional Outlook

8. Company Profiles

9. Research Methodology & Scope

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/slactg

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more from the original source:
Global Drug Discovery Market 2019-2027: Market is Poised to Grow at a CAGR of 8.28% from 2019-2027 - PRNewswire

A leading research firm, Zion Market Research added a latest industry report on "Global Pharmacogenomics Market" consisting of 110+ pages during the forecast period and Pharmacogenomics Market report offers a comprehensive research updates and information related to market growth, demand, opportunities in the global Pharmacogenomics Market.

According to the report the Pharmacogenomics Market: Leading Segments and their Growth Drivers

The Pharmacogenomics Market report provides in-depth analysis and insights into developments impacting businesses and enterprises on global and regional level. The report covers the global Pharmacogenomics Market performance in terms of revenue contribution from various segments and includes a detailed analysis of key trends, drivers, restraints, and opportunities influencing revenue growth of the global consumer electronics market.This report studies the global Pharmacogenomics Market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Pharmacogenomics Market by companies, region, type and end-use industry.

Request a Free Sample Report on Pharmacogenomics Market:https://www.zionmarketresearch.com/sample/pharmacogenomics-market

The Pharmacogenomics Market report mainly includes the major company profiles with their annual sales & revenue, business strategies, company major products, profits, industry growth parameters, industry contribution on global and regional level.This report covers the global Pharmacogenomics Market performance in terms of value and volume contribution. This section also includes major company analysis of key trends, drivers, restraints, challenges, and opportunities, which are influencing the global Pharmacogenomics Market. Impact analysis of key growth drivers and restraints, based on the weighted average model, is included in this report to better equip clients with crystal clear decision-making insights.

The Pharmacogenomics Market research report mainly segmented into types, applications and regions.The market overview section highlights the Pharmacogenomics Market definition, taxonomy, and an overview of the parent market across the globe and region wise.To provide better understanding of the global Pharmacogenomics Market, the report includes in-depth analysis of drivers, restraints, and trends in all major regions namely, Asia Pacific, North America, Europe, Latin America and the Middle East & Africa, which influence the current market scenario and future status of the global Pharmacogenomics Market over the forecast period.

Get Free PDF Brochure of this Report: https://www.zionmarketresearch.com/requestbrochure/pharmacogenomics-market

The Pharmacogenomics Market report provides company market size, share analysis in order to give a broader overview of the key players in the market. Additionally, the report also includes key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, product and regional expansion of major participants involved in the market on the global and regional basis.

Major Company Profiles Covered in This Report:

Dynamic DNA Laboratories, Abbott Laboratories, Empire Genomics, LLC, Illumina, Inc., F. Hoffmann-La Roche Ltd., Myriad Genetics Inc., OneOme LLC, Thermo Fisher Scientific, Inc., and OPKO Health, Inc. among others.

Some of the major objectives of this report:

1) To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Pharmacogenomics Market.

2. To provide insights about factors affecting the market growth. To analyze the Pharmacogenomics Market based on various factors- price analysis, supply chain analysis, porter five force analysis etc.

3. To provide historical and forecast revenue of the Pharmacogenomics Market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World.

4. Country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

7. Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Pharmacogenomics Market.

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research

244 Fifth Avenue, Suite N202

New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll Free No.1-855-465-4651

Email: sales@zionmarketresearch.com

Website: https://www.zionmarketresearch.com

See the article here:
Pharmacogenomics Market: Leading Segments and their Growth Drivers - TheInfobiz

Clinical laboratories with strong digital and information technology capabilities may find opportunities in this growing field of healthcare

Digital therapeutics (DTx), a growing trend in life sciences technology, is emerging as a popular form of connected healthcare physicians can use to transform patient behavior and improve clinical outcomes. This development may create opportunities for IT-savvy clinical laboratories.

The software applications (apps) and hardware monitoring devices involved in digital therapeutics enable physicians and patients to target and alter specific behaviors that affect certain medical conditions, such as substance abuse or depression. Combined with or without drugs, digital therapeutics are achieving positive results, according to the United Kingdoms PwC (PricewaterhouseCoopers) Health Research Institute (PwC HRI).

Clinical laboratory leaders engaged in precision medicine and pharmacogenomic initiatives will be intrigued by potential opportunities to support digital therapeutics. The FDAs Digital Software Precertification Program has already begun awarding approvals for digital therapeutics that address diabetes and central nervous system disorders, in addition to substance abuse and birth control.

And more FDA approvals for digital therapeutics are expectedin 2020, PwC HRI predicted.

Pharmaceutical and Tech Companies Collaborate on DigitalTherapeutics

A PwC report, titled, Top Health Industry Issues of 2019: The New Health Economy Comes of Age, describes digital therapeutics is an emerging health discipline that uses technology to augment or even replace active drugs in disease treatment.

The report goes on to state that digital therapeutics isreshaping the landscape for new medicines, product reimbursement and regulatoryoversight [and that] new data sharing processes and payment models will beestablished to integrate these products into the broader treatment arsenal andregulatory structure for drug and device approvals.

Connected health services, the report continues, enabled by devices that transmit data or connect to the Internet, give additional visibility into care delivery and new ways to improve patient outcomes.

Digital therapeutics combine apps and monitoring devices forthe management and treatment of medical conditions. While similar to customerwellness apps, digital therapeutics focus on specific clinical outcomes.

The non-profit Digital Therapeutics Alliance says that, unlike common wellness apps, digital therapeutics possess the unique ability to incorporate additional functionalities into a comprehensive portfolio of synchronous products and services. This includes potential integration with mobile health platforms; the provision of complementary diagnostic or adherence interventions; the ability to pair with devices, sensors, or wearables; the delivery of interventions remotely; and integration into electronic prescribing, dispensing, and medical record platforms.

Digital therapeutics are the next frontier, Sai Jasti, Chief Data and Analytics Officer, GlaxoSmithKline (NYSE:GSK), told PwC HRI. I think we will see a lot more collaboration between pharmaceutical and technology companies to drive this forward, ultimately to the benefit of patients.

Digital Therapeutics That Already Have FDA Approval

Digital therapeutics and their connected devices are subjectto the approval process of the federal Food and Drug Administration (FDA), andsome have already received that coveted clearance:

Digital technologies and data science have incredible potential to unlock the next chapter of medical innovation and to help individuals finally take control of their own health in a meaningful way, said Richard Francis, Division Head and CEO, Sandoz, in a press release. New digital therapeutics such as reSET-O also have the potential to fundamentally change how patients interact with their therapies and thus improve patient outcomes.

Both reSET and reSET-O are software mobile apps that use cognitive behavioral therapy (CBT) to help individuals struggling with addictions.

Nearly 50,000 drug overdose deaths involving opioids, including prescription pain medications and heroin, took place in the U.S. in 2017, said Corey McCann, MD, PhD, President and CEO of Pear Therapeutics, in the press release following receiving FDA approval. There is an urgent need for new and innovative therapeutics to address this public health epidemic. This groundbreaking decision by the FDA ushers in a new standard for treating patients with Opioid Use Disorder and it signals a new path for therapeutic software to be used in conjunction with pharmacotherapy to improve efficacy.

We know that women are more likely to use contraceptive methods when they have a variety of methods available to them, and the reality is that not every method is going to work for every woman, Rebecca Simmons, PhD, Research Assistant Professor, Department of Obstetrics and Gynecology, University of Utah, told Health. This is really exciting, in the sense that the more methods we have, the more likely it is that people can find something that works for themand then can avoid unwanted pregnancy.

The role that technology plays in allowing patients to capture meaningful data about whats happening with their heartat the moment when its happening, like the functionality of an on-demand ECGcould be significant in new clinical care models and shared decision-making between people and their healthcare providers, said Nancy Brown, CEO of the American Heart Association, in a press release.

Patients, Providers, and Big Pharma All Like DigitalTherapeutics

There is some evidence that patients and healthcareproviders are intrigued and willing to try digital therapeutics. In a PwC HRI survey,more than 50% of respondents said they would be somewhat or very likely to tryan FDA-approved app or online tool for treatment of a medical condition.

Pharmaceutical companies also are interested in digital therapeutics. A 2018 PwC HRI survey found that 80% of pharmaceutical executives had plans to invest in digital therapeutics in the near future.

A 2019 PwC article, titled, Digital Health Products Need Evidence and Buy-In to Succeed, states that drug companies see the following opportunities for DTx to improve the patient experience:

With precision medicine and pharmacogenetics, clinical laboratoriescould play an essential role in supporting digital therapeutics in the future. Butto truly be competitive in this space and take advantage of the opportunity, medicallaboratories will need to increase their information technology and digitalcapabilities.

JP Schlingman

Related Information:

Digital Therapeutics and Connected Care Reshape the Life Sciences Industry

The Emerging World of Digital Therapeutics

Top Health Industry Issues of 2019: The New Health Economy Comes of Age

Digital Therapeutics: Combining Technology and Evidence-based Medicine to Transform Personalized Patient Care

Everything You Need to Know About the Controversial New Birth Control App

Digital Health Software Precertification (Pre-Cert) Program

Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for Reset-O to Treat Opioid Use Disorder

Everything You Need to Know About the Controversial New Birth Control App

More than Half of Patients Willing to Use Digital Therapeutic, Study Says

ECG App and Irregular Heart Rhythm Notification Available Today on Apple Watch

Digital Health Products Need Evidence and Buy-in to Succeed

Life Sciences May See Accelerated Digital Health Pathway as Soon as 2020

See the original post here:
FDA Approves Digital Therapeutics Technologies to Treat Patient Behavioral Conditions That Interfere with Positive Healthcare Outcomes - DARKDaily.com...

NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium

NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology (ASCO).

The Symposium, held at the Moscone West Building in San Francisco, CA from January 23-25, provides evidence-based teaching methods and cutting-edge learning science to a diverse audience of leaders in oncology education, doctors and care teams.

NantHealths presentation utilized data on whole exome (WES) DNA tumor and paired germline and matched deep whole transcriptomic sequencing (RNA-Seq) to identify a higher percentage of CRC patients with HER2 signaling than conventional methods of immunohistochemistry (IHC) or fluorescence in-situ hybridization (FISH). ERBB2 (HER2) gene expression was evaluated using NantOmics Nant50 gene classifier, which separates patients into subgroups that have been well established in breast cancer. The application of this tool to colorectal cancer proved surprising with greater than expected HER2 positive patients with a normally expected distribution of CMS classification (consensus molecular subtype in CRC). This finding suggests a possible utility for this tool in a new clinical setting. In addition, the HER2 enriched group did not show differentially expressed mutations in other targetable genes such as PIK3CA and BRAF, highlighting the potential importance of HER2 targeting in this population.

"Our analysis shows that conventional testing methods may miss potentially actionable HER2 signaling in CRC patients," said Sandeep "Bobby" Reddy, MD, Chief Medical Officer, NantHealth. "The significant difference suggests that up to 40% more patients may be eligible for HER2 directed therapies, which has implications for drug development and clinical trials."

Title: "Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients"

Authors: Sandeep K. Reddy, M.D., Tara Elisabeth Seery, M.D., Christopher W. Szeto, Ph.D.

Poster Session and Number: Poster session C (Board #A14)

Location: Moscone West Building

Date and Time: January 25, 2020, 6:30-7:55 AM PT and 12:15-1:45 PM PT

About NantHealth:

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealths comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), connected care solutions that deliver medical device interoperability (DCX device connectivity platform and VCX patient vitals software) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer). For more information, please visit http://www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

About NantOmics:

NantOmics, a member of the NantWorks ecosystem of companies, invented and developed the technologies that drive NantHealths GPS Cancer platform. GPS Cancer provides actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing molecular variances and profiles that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances from DNA to RNA to protein to drug. Having pioneered tumor-normal DNA sequencing and introduced whole RNA transcriptomic analysis to better inform clinical treatment decisions, NantOmics has provided molecular insights for thousands of cancer patients.

NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time and correlating proteomic pathway analysis with quantitative gene expression and pharmacogenomic signatures, which guides the use of immunotherapies, chemotherapies and targeted therapies. Clinical studies for neoepitope vaccines using NantOmics proprietary technologies and novel artificial intelligence platforms are currently underway. For more information please visit http://www.nantomics.com.

Story continues

Forward-Looking Statements: NantHealth

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on managements current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200125005009/en/

Contacts

NANT Jen HodsonJen@nant.com 562-397-3639

Read more here:
Data from NantHealths GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients - Yahoo Finance

Latest Market Research Report onDrug Discovery Technologies Market size | Industry Segment by Applications (Biopharmaceutical companies, Pharmaceutical companies, Research institutes and Biotech companies), by Type (Biochips, High throughput screening, Pharmacogenomics, Genomics, Bioanalytical instruments, Bioinformatics, Nanotechnology and Others), Regional Outlook, Market Demand, Latest Trends, Drug Discovery Technologies Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The research report on Drug Discovery Technologies market has integrated the analysis of different factors that boost the Drug Discovery Technologies markets growth. It establishes trends, restraints and drivers that transform the Drug Discovery Technologies market in either a positive or negative manner. The detailed information is based on current Drug Discovery Technologies market trends and historic achievements.

This section of the report identifies various key manufacturers of the Drug Discovery Technologies market. It helps the reader understand the strategies and associations that players are focusing on combat competition in the Drug Discovery Technologies market. The Analysis report on Drug Discovery Technologies Market provides a significant in-depth analysis of the market.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/55919

Top key playersof industry are covered in Drug Discovery Technologies Market Research Report:

Split by product type,with production, revenue, price, market share and growth rate of each type, can be divided into:

Split by application,this report focuses on consumption, market share and growth rate of Drug Discovery Technologies market in each application and can be divided into:

The foremost points are labelled in detail which are covered in this Drug Discovery Technologies Market Report:

The research process begins with internal and external sources to obtain qualitative and quantitative information related to the Drug Discovery Technologies market. It also provides an overview and forecast for the Drug Discovery Technologies market based on all the segmentation provided for the global region.The predictions highlighted in the Drug Discovery Technologies market share report have been derived using verified research procedures and assumptions. By doing so, the research report serves as a repository of analysis and information for every component of the Drug Discovery Technologies market.

The Drug Discovery Technologies market has shown growing trends over the years and anticipations are made that the Drug Discovery Technologies market size would grow at a speedy pace in the upcoming years. Growth in the Drug Discovery Technologies market would be primarily driven by application areas such as Biopharmaceutical companies, Pharmaceutical companies, Research institutes and Biotech companies and product types segment like Biochips, High throughput screening, Pharmacogenomics, Genomics, Bioanalytical instruments, Bioinformatics, Nanotechnology and Others.

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/55919

See the article here:
Drug Discovery Technologies Market Research, Recent Trends and Growth Forecast 2 - News by aeresearch